Background: Activity-related dyspnea is the main contributor to the altered quality of life in diffuse parenchymal lung diseases (DPLD). Instruments pertaining to dyspnea are classified as pertaining to domains of sensory-perceptual experience, affective distress or symptom/disease impact; whether these domains are equally related to lung function impairments remains to be established. Objectives: They were to assess the relationships between two domains of dyspnea (sensory-perceptual experience and symptom impact) and pulmonary function tests according to their evaluation of ventilatory demand, capacity and drive in patients suffering from DPLD. Methods: Fifty patients were prospectively enrolled (median age, 58 years; 25 women) and underwent spirometry, body plethysmography, measurements of lung diffusion for carbon monoxide (DLCO) and nitric oxide, maximal airway pressures (capacity and demand assessments), mouth occlusion pressure at 0.1 s (P0.1: respiratory drive assessment) and a 6-min walk test with Borg score assessment (dyspnea: sensory domain). The impact domain of dyspnea was evaluated using the baseline dyspnea index. Results: The sensory domain of dyspnea was linked to demand (CO transfer coefficient, kCO) only, while the impact domain was independently linked to demand and capacity (kCO and forced vital capacity, respectively). Among resting pulmonary function tests, both P0.1 and DLCO allowed the assessment of these two domains of dyspnea. Conclusions: In DPLD, the sensory-perceptual domain of dyspnea is mainly linked to alterations in ventilatory demand while the impact domain is related to both demand and capacity. DLCO that assesses both demand and capacity and P0.1 were the strongest correlates of dyspnea.

1.
Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G, Brun M, Gupta A, Juhel N, Kluglich M, du Bois RM: Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011;365:1079-1087.
2.
Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW: A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010;363:620-628.
3.
Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, Nicholson AG, Verbeken EK, Verschakelen J, Flower CD, Capron F, Petruzzelli S, De Vuyst P, van den Bosch JM, Rodriguez-Becerra E, Corvasce G, Lankhorst I, Sardina M, Montanari M: High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005;353:2229-2242.
4.
Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH: A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999;341:1264-1269.
5.
Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Muller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schunemann HJ: An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
6.
Parshall MB, Schwartzstein RM, Adams L, Banzett RB, Manning HL, Bourbeau J, Calverley PM, Gift AG, Harver A, Lareau SC, Mahler DA, Meek PM, O'Donnell DE: An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med 2012;185:435-452.
7.
Mura M, Ferretti A, Ferro O, Zompatori M, Cavalli A, Schiavina M, Fabbri M: Functional predictors of exertional dyspnea, 6-min walking distance and HRCT fibrosis score in idiopathic pulmonary fibrosis. Respiration 2006;73:495-502.
8.
Sanchez O, Caumont-Prim A, Gillet-Juvin K, Callens E, Graba S, Essalhi M, Chevalier-Bidaud B, Israël-Biet D, Mahut B, Delclaux C: Activity-related dyspnea is not modified by psychological status in people with COPD, interstitial lung disease or obesity. Respir Physiol Neurobiol 2012;182:18-25.
9.
American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002;165:277-304.
10.
Fletcher R, Jonson B, Cumming G, Brew J: The concept of deadspace with special reference to the single breath test for carbon dioxide. Br J Anaesth 1981;53:77-88.
11.
Anonymous: ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-117.
12.
Troosters T, Gosselink R, Decramer M: Six minute walking distance in healthy elderly subjects. Eur Respir J 1999;14:270-274.
13.
Callens E, Graba S, Gillet-Juvin K, Essalhi M, Bidaud-Chevalier B, Peiffer C, Mahut B, Delclaux C: Measurement of dynamic hyperinflation after a 6-minute walk test in patients with COPD. Chest 2009;136:1466-1472.
14.
Muller E, Harzendorf E, Merker G, Pleger E, Wilke A, Vogel J: Theoretical and experimental studies of the diagnostic relevance and comparability of mechanical oscillation parameters (in German). Pneumologie 1989;43:339-347.
15.
Oostveen E, MacLeod D, Lorino H, Farre R, Hantos Z, Desager K, Marchal F: The forced oscillation technique in clinical practice: methodology, recommendations and future developments. Eur Respir J 2003;22:1026-1041.
16.
Stanojevic S, Wade A, Stocks J, Hankinson J, Coates AL, Pan H, Rosenthal M, Corey M, Lebecque P, Cole TJ: Reference ranges for spirometry across all ages: a new approach. Am J Respir Crit Care Med 2008;177:253-260.
17.
Wilson SH, Cooke NT, Edwards RH, Spiro SG: Predicted normal values for maximal respiratory pressures in Caucasian adults and children. Thorax 1984;39:535-538.
18.
Concato J, Peduzzi P, Holford TR, Feinstein AR: Importance of events per independent variable in proportional hazards analysis. I. Background, goals, and general strategy. J Clin Epidemiol 1995;48:1495-1501.
19.
Peduzzi P, Concato J, Feinstein AR, Holford TR: Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol 1995;48:1503-1510.
20.
Rothman KJ: No adjustments are needed for multiple comparisons. Epidemiology 1990;1:43-46.
21.
von Leupoldt A, Ambruzsova R, Nordmeyer S, Jeske N, Dahme B: Sensory and affective aspects of dyspnea contribute differentially to the Borg scale's measurement of dyspnea. Respiration 2006;73:762-768.
22.
Carrieri-Kohlman V, Donesky-Cuenco D, Park SK, Mackin L, Nguyen HQ, Paul SM: Additional evidence for the affective dimension of dyspnea in patients with COPD. Res Nurs Health 2010;33:4-19.
23.
Wilson RC, Jones PW: Differentiation between the intensity of breathlessness and the distress it evokes in normal subjects during exercise. Clin Sci (Lond) 1991;80:65-70.
24.
Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG, MacIntyre NR, McKay RT, Wanger JS, Anderson SD, Cockcroft DW, Fish JE, Sterk PJ: Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 2000;161:309-329.
25.
O'Donnell DE, Chau LK, Webb KA: Qualitative aspects of exertional dyspnea in patients with interstitial lung disease. J Appl Physiol 1998;84:2000-2009.
26.
Banzett RB, Pedersen SH, Schwartzstein RM, Lansing RW: The affective dimension of laboratory dyspnea: air hunger is more unpleasant than work/effort. Am J Respir Crit Care Med 2008;177:1384-1390.
27.
Renzi G, Milic-Emili J, Grassino AE: The pattern of breathing in diffuse lung fibrosis. Bull Eur Physiopathol Respir 1982;18:461-472.
28.
Whitelaw WA, Derenne JP, Milic-Emili J: Occlusion pressure as a measure of respiratory center output in conscious man. Respir Physiol 1975;23:181-199.
29.
Mahler DA, Harver A, Rosiello R, Daubenspeck JA: Measurement of respiratory sensation in interstitial lung disease. Evaluation of clinical dyspnea ratings and magnitude scaling. Chest 1989;96:767-771.
30.
O'Donnell DE, Webb KA: Breathlessness in patients with severe chronic airflow limitation. Physiologic correlations. Chest 1992;102:824-831.
31.
Mahut B, Chevalier-Bidaud B, Plantier L, Essalhi M, Callens E, Graba S, Gillet-Juvin K, Valcke-Brossollet J, Delclaux C: Diffusing capacity for carbon monoxide is linked to ventilatory demand in patients with chronic obstructive pulmonary disease. COPD 2012;9:16-21.
32.
Ryerson CJ, Berkeley J, Carrieri-Kohlman VL, Pantilat SZ, Landefeld CS, Collard HR: Depression and functional status are strongly associated with dyspnea in interstitial lung disease. Chest 2011;139:609-616.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.